Topoisomerase I inhibitors market set to reach $7.31 billion by 2030

A new Business Research Company report says the topoisomerase I inhibitors market will grow from $5.46 billion in 2025 to $5.79 billion in 2026, driven by cancer treatment demand and drug development. The market is forecast to hit $7.31 billion by 2030, with North America leading now and Asia-Pacific expected to grow fastest.

Why it matters: - Topoisomerase I inhibitors are used in cancer treatment, so market growth tracks with rising global cancer burden and demand for oncology drugs. - The report points to a shift toward new non-camptothecin options, oral and injectable formats, and more targeted therapies, all of which could broaden treatment access. - The forecast suggests continued commercial momentum for drugmakers, hospitals, and clinics focused on anticancer medicines.

What happened: - The Business Research Company released a report on the topoisomerase I inhibitors market covering 2026 to 2035. - The market is projected to rise from $5.46 billion in 2025 to $5.79 billion in 2026, a 6.1% CAGR. - The market is forecast to reach $7.31 billion by 2030, growing at a 6.0% CAGR. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Topoisomerase I inhibitors target the topoisomerase I enzyme, which helps relieve torsional stress on DNA during replication and transcription. - The drugs bind to the enzyme-DNA complex and block the re-ligation step that repairs DNA breaks. - That disruption increases DNA damage and can lead to cell death, especially in rapidly dividing cancer cells. - Growth has been supported by limited availability of these inhibitors, heavy reliance on camptothecin derivatives, rising cancer prevalence, expansion of oncology hospital services, and slow progress on non-camptothecin compounds. - Future growth is linked to new non-camptothecin inhibitors such as lmp-400 and indenoisoquinolines, plus wider availability of oral and injectable forms. - The report also cites growing oncology research and clinical trials, faster regulatory approvals, and stronger drug commercialization efforts. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - The report adds market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The company offers a free sample of the report and the full report.

Between the lines: - The report frames cancer incidence as the main demand engine, with the World Health Organization projecting cancer cases to climb by more than 35 million by 2050, a 77% increase from 20 million cases in 2022. - The emphasis on non-camptothecin inhibitors suggests the market is trying to move beyond older drug classes and reduce dependence on a narrow set of therapies. - Regional growth patterns indicate the market is still anchored in established healthcare systems, while expansion is likely to accelerate in faster-growing Asia-Pacific markets.

What's next: - The market is expected to keep expanding as more candidates move through research and clinical trials. - Regulatory approvals and commercialization efforts will likely shape how quickly new inhibitors reach patients. - Wider use of oral and injectable oncology drugs could become a key competitive advantage for developers.

The bottom line: - The topoisomerase I inhibitors market is on a steady growth path, backed by cancer demand, pipeline innovation and broader global oncology spending.